Articles by Patricia Van Arnum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Patricia Van Arnum

Elucidating Heterocyclic Chemistry in Pharmaceuticals

Researchers at the Scripps Research Institute advance heteorcylic chemistry trhough new reagents and reaction-tracking techniques.
Jun 2, 2013

Researchers at the Scripps Research Institute advance heteorcylic chemistry trhough new reagents and reaction-tracking techniques.

Small-Molecule Drug Development: Recent Study Suggests Limited Binding Sites

A recent study of computer-created and natural proteins suggests the number of sites where small-molecule drugs can bind to proteins is limited, thereby narrowing how to mitigate side effects through drug design.
Jun 2, 2013

A recent study of computer-created and natural proteins suggests the number of sites where small-molecule drugs can bind to proteins is limited, thereby narrowing how to mitigate side effects through drug design.

FDA Issues Draft Guidance on Contract Manufacturing

The draft guidance describes how quality agreements can be used to delineate the responsibilities of contract manufacturers involved in the cGMP manufacture of APIs and finished drug products.
May 28, 2013

The draft guidance describes how quality agreements can be used to delineate the responsibilities of contract manufacturers involved in the cGMP manufacture of APIs and finished drug products.

FDA Issues Warning Letter to Boehringer Ingelheim for cGMP Violations

Company receives notice from FDA for not fully investigating foreign particles in APIs and finished products made from its facility in Ingelheim am Rhein, Germany.
May 28, 2013

Company receives notice from FDA for not fully investigating foreign particles in APIs and finished products made from its facility in Ingelheim am Rhein, Germany.

Pharma Industry Participates in Vaccine Initiatives

The Global Vaccine Action plan maps out a strategy to increase access and R&D for vaccines.
May 3, 2013

The Global Vaccine Action plan maps out a strategy to increase access and R&D for vaccines.

The New Normal In Biotech Financing

Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.
May 3, 2013

Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.

Big Pharma's Investment in Biologics

Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Sanofi, and Roche are among the companies expanding biologic-based manufacturing capacity.
May 3, 2013

Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Sanofi, and Roche are among the companies expanding biologic-based manufacturing capacity.

Intellectual Property Battles in Solid-State Chemistry

The rejection by India's Supreme Court on Novartis' Glivec/Gleevec (imatinib mesylate) and other recent case law raise important issues on patent strategies for solid forms.
May 2, 2013

The rejection by India's Supreme Court on Novartis' Glivec/Gleevec (imatinib mesylate) and other recent case law raise important issues on patent strategies for solid forms.

Academic and Public Partnerships in Solid-State Chemistry

Solid-state chemistry is an important part of drug development, and public research is advancing the field.
May 2, 2013

Solid-state chemistry is an important part of drug development, and public research is advancing the field.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
75%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
0%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
0%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Click here